TY - JOUR
T1 - Neurologic phenotypes associated with acanthocytosis
AU - Walker, R. H.
AU - Jung, H. H.
AU - Dobson-Stone, C.
AU - Rampoldi, L.
AU - Sano, A.
AU - Tison, F.
AU - Danek, A.
N1 - Funding Information:
This review resulted from discussions at the Second International Neuroacanthocytosis Symposium, supported by the Movement Disorder Society, Montreal Neurological Hospital and Institute, McGill University, The Advocacy for Neuroacanthocytosis Patients, the High Q Foundation, Inc., and John Grooms, Working with Disabled People. Carol Dobson-Stone is supported by an EMBO postdoctoral fellowship.
PY - 2007/1
Y1 - 2007/1
N2 - The term "neuroacanthocytosis" is normally used to refer to autosomal recessive chorea-acanthocytosis and X-linked McLeod syndrome, but there are other movement disorders in which erythrocyte acanthocytosis may also be seen, such as Huntington disease-like 2 and pantothenate kinase-associated neurodegeneration. Disorders of serum lipoproteins such as Bassen-Kornzweig disease form a distinct group of neuroacanthocytosis syndromes in which ataxia is observed, but movement disorders are not seen. Genetic testing has enabled us to distinguish between these disorders, even when there are considerable similarities between phenotypes. Improved detection is important for accurate genetic counseling, for monitoring for complications, and, it is hoped, for implementing causal treatments, once these become available. As in other neurodegenerative conditions, animal models are a promising strategy for the development of such therapies.
AB - The term "neuroacanthocytosis" is normally used to refer to autosomal recessive chorea-acanthocytosis and X-linked McLeod syndrome, but there are other movement disorders in which erythrocyte acanthocytosis may also be seen, such as Huntington disease-like 2 and pantothenate kinase-associated neurodegeneration. Disorders of serum lipoproteins such as Bassen-Kornzweig disease form a distinct group of neuroacanthocytosis syndromes in which ataxia is observed, but movement disorders are not seen. Genetic testing has enabled us to distinguish between these disorders, even when there are considerable similarities between phenotypes. Improved detection is important for accurate genetic counseling, for monitoring for complications, and, it is hoped, for implementing causal treatments, once these become available. As in other neurodegenerative conditions, animal models are a promising strategy for the development of such therapies.
UR - http://www.scopus.com/inward/record.url?scp=33846097303&partnerID=8YFLogxK
U2 - 10.1212/01.wnl.0000250356.78092.cc
DO - 10.1212/01.wnl.0000250356.78092.cc
M3 - Review article
C2 - 17210889
AN - SCOPUS:33846097303
SN - 0028-3878
VL - 68
SP - 92
EP - 98
JO - Neurology
JF - Neurology
IS - 2
ER -